"Tumor angiogenesis"@en . "Tumor angiogenesis represents efficient mechanism that allows survival of tumor cells and promotes tumor growth. Antiangiogenic strategies are widely tested in various tumor types. The initial therapeutic attempts were focused on the inhibition of vascular epithelial growth factor signalling cascade and now research continues on other angiogenic signalling pathways (Tie, FGF)."@en . "Novotn\u00FD, Jan" . . "N\u00E1dorov\u00E1 angiogeneze" . "Tumor angiogenesis"@en . . . "2"^^ . "N\u00E1dorov\u00E1 angiogeneze" . "N\u00E1dorov\u00E1 angiogeneze"@cs . . "Angiogenesis; VEGF; TIE; angiopoietin; DLL4"@en . "2"^^ . . "273507" . "RIV/00064165:_____/10:7542!RIV11-MZ0-00064165" . . . . "N\u00E1dorov\u00E1 angiogeneze"@cs . . "CZ - \u010Cesk\u00E1 republika" . . . "N\u00E1dorov\u00E1 angiogeneze p\u0159edstavuje pro n\u00E1dorov\u00E9 bu\u0148ky \u00FA\u010Dinn\u00FD mechanizmus vlastn\u00EDho p\u0159e\u017Eit\u00ED a \u0161\u00ED\u0159en\u00ED se do vzd\u00E1len\u00FDch tk\u00E1n\u00ED. Nen\u00ED proto p\u0159ekvapen\u00EDm, \u017Ee se antiangiogenn\u00ED strategie \u0161iroce studuje a uplat\u0148uje v l\u00E9\u010Db\u011B. Po prvn\u00EDch klinicky pou\u017E\u00EDvan\u00FDch molekul\u00E1ch, je\u017E p\u016Fsob\u00ED v oblasti receptoru pro vaskul\u00E1rn\u00ED epiteli\u00E1ln\u00ED r\u016Fstov\u00FD faktor (VEGFR) a\u0165 ji\u017E vyv\u00E1z\u00E1n\u00EDm VEGF, \u010Di inhibic\u00ED intracelul\u00E1rn\u00ED dom\u00E9ny VEGFR se pozornost v\u011Bdc\u016F obrac\u00ED k dal\u0161\u00EDm c\u00EDl\u016Fm, kter\u00E9 jsou sou\u010D\u00E1st\u00ED angiogenn\u00EDch kask\u00E1d (proteiny TIE, VHL a dal\u0161\u00ED)." . . "RIV/00064165:_____/10:7542" . "3"^^ . . "I, Z(MSM0021620808)" . "Zik\u00E1n, Michal" . "[2ED1FBC596FE]" . "1212-7973" . . "N\u00E1dorov\u00E1 angiogeneze p\u0159edstavuje pro n\u00E1dorov\u00E9 bu\u0148ky \u00FA\u010Dinn\u00FD mechanizmus vlastn\u00EDho p\u0159e\u017Eit\u00ED a \u0161\u00ED\u0159en\u00ED se do vzd\u00E1len\u00FDch tk\u00E1n\u00ED. Nen\u00ED proto p\u0159ekvapen\u00EDm, \u017Ee se antiangiogenn\u00ED strategie \u0161iroce studuje a uplat\u0148uje v l\u00E9\u010Db\u011B. Po prvn\u00EDch klinicky pou\u017E\u00EDvan\u00FDch molekul\u00E1ch, je\u017E p\u016Fsob\u00ED v oblasti receptoru pro vaskul\u00E1rn\u00ED epiteli\u00E1ln\u00ED r\u016Fstov\u00FD faktor (VEGFR) a\u0165 ji\u017E vyv\u00E1z\u00E1n\u00EDm VEGF, \u010Di inhibic\u00ED intracelul\u00E1rn\u00ED dom\u00E9ny VEGFR se pozornost v\u011Bdc\u016F obrac\u00ED k dal\u0161\u00EDm c\u00EDl\u016Fm, kter\u00E9 jsou sou\u010D\u00E1st\u00ED angiogenn\u00EDch kask\u00E1d (proteiny TIE, VHL a dal\u0161\u00ED)."@cs . "24" . "3" . . . "Klinick\u00E1 farmakologie a farmacie" . . . .